Precision BioSciences (NASDAQ:DTIL) Trading Down 3.8% – Time to Sell?

Precision BioSciences, Inc. (NASDAQ:DTIL)’s stock price dropped 3.8% during mid-day trading on Wednesday . The company traded as low as $3.90 and last traded at $4.01. Approximately 202,655 shares changed hands during mid-day trading, a decline of 5% from the average daily volume of 214,267 shares. The stock had previously closed at $4.17.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Precision BioSciences in a report on Monday, December 22nd. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $60.00.

Precision BioSciences Stock Performance

The company has a market capitalization of $53.17 million, a price-to-earnings ratio of -0.48 and a beta of 1.20. The firm has a fifty day simple moving average of $4.62 and a 200 day simple moving average of $5.12. The company has a debt-to-equity ratio of 1.35, a current ratio of 3.45 and a quick ratio of 3.45.

Precision BioSciences (NASDAQ:DTIL) last announced its earnings results on Monday, November 3rd. The company reported ($1.84) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.31) by ($1.53). The business had revenue of $0.01 million for the quarter, compared to analysts’ expectations of $5.40 million. Precision BioSciences had a negative net margin of 11,977.36% and a negative return on equity of 233.77%. During the same quarter last year, the business earned ($2.25) EPS. On average, analysts anticipate that Precision BioSciences, Inc. will post -1.23 earnings per share for the current fiscal year.

Institutional Trading of Precision BioSciences

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Vanguard Personalized Indexing Management LLC purchased a new position in Precision BioSciences in the 3rd quarter valued at about $72,000. Virtu Financial LLC acquired a new position in shares of Precision BioSciences during the third quarter valued at approximately $84,000. GSA Capital Partners LLP purchased a new position in shares of Precision BioSciences in the third quarter valued at approximately $98,000. Velan Capital Investment Management LP purchased a new position in shares of Precision BioSciences in the third quarter valued at approximately $110,000. Finally, Citadel Advisors LLC acquired a new stake in shares of Precision BioSciences in the third quarter worth approximately $122,000. Hedge funds and other institutional investors own 37.99% of the company’s stock.

Precision BioSciences Company Profile

Precision BioSciences is a clinical‐stage genome editing company that leverages its proprietary ARCUS platform to develop targeted gene therapies. ARCUS, an engineered nuclease derived from a naturally occurring enzyme, enables precise DNA modifications for both in vivo and ex vivo applications. The company’s pipeline spans genetic diseases—including rare monogenic disorders—and immuno‐oncology, where it is advancing allogeneic cell therapy candidates designed to address hematologic malignancies and solid tumors.

Founded in 2006 as a spin‐out from research at the University of North Carolina, Precision BioSciences is headquartered in Durham, North Carolina, with additional research and manufacturing capabilities located in the Research Triangle Park area.